136 related articles for article (PubMed ID: 32079522)
21. Expression Profiling of a Human Thyroid Cell Line Stably Expressing the BRAFV600E Mutation.
Kim BA; Jee HG; Yi JW; Kim SJ; Chai YJ; Choi JY; Lee KE
Cancer Genomics Proteomics; 2017 Jan; 14(1):53-67. PubMed ID: 28031237
[TBL] [Abstract][Full Text] [Related]
22. Cellular apoptosis susceptibility (CAS) is overexpressed in thyroid carcinoma and maintains tumor cell growth: A potential link to the BRAFV600E mutation.
Holzer K; Drucker E; Oliver S; Winkler J; Eiteneuer E; Herpel E; Breuhahn K; Singer S
Int J Oncol; 2016 Apr; 48(4):1679-87. PubMed ID: 26892809
[TBL] [Abstract][Full Text] [Related]
23. c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.
Byeon HK; Na HJ; Yang YJ; Kwon HJ; Chang JW; Ban MJ; Kim WS; Shin DY; Lee EJ; Koh YW; Yoon JH; Choi EC
Mol Carcinog; 2016 Nov; 55(11):1678-1687. PubMed ID: 26456083
[TBL] [Abstract][Full Text] [Related]
24. ERK phosphorylation is not increased in papillary thyroid carcinomas with BRAF(V600E) mutation compared to that of corresponding normal thyroid tissues.
Kim SW; Kim HK; Lee JI; Jang HW; Choe JH; Kim JH; Kim JS; Hur KY; Kim JH; Chung JH
Endocr Res; 2013; 38(2):89-97. PubMed ID: 23544999
[TBL] [Abstract][Full Text] [Related]
25. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G
Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714
[TBL] [Abstract][Full Text] [Related]
26. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
27.
Hill KS; Roberts ER; Wang X; Marin E; Park TD; Son S; Ren Y; Fang B; Yoder S; Kim S; Wan L; Sarnaik AA; Koomen JM; Messina JL; Teer JK; Kim Y; Wu J; Chalfant CE; Kim M
Mol Cancer Res; 2019 Feb; 17(2):583-593. PubMed ID: 30355677
[TBL] [Abstract][Full Text] [Related]
28. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells.
Melillo RM; Castellone MD; Guarino V; De Falco V; Cirafici AM; Salvatore G; Caiazzo F; Basolo F; Giannini R; Kruhoffer M; Orntoft T; Fusco A; Santoro M
J Clin Invest; 2005 Apr; 115(4):1068-81. PubMed ID: 15761501
[TBL] [Abstract][Full Text] [Related]
29. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
[TBL] [Abstract][Full Text] [Related]
30. The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside.
Choi HJ; Kim TY; Chung N; Yim JH; Kim WG; Kim JA; Kim WB; Shong YK
J Endocrinol; 2011 Oct; 211(1):79-85. PubMed ID: 21795305
[TBL] [Abstract][Full Text] [Related]
31. Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF.
Cisowski J; Sayin VI; Liu M; Karlsson C; Bergo MO
Oncogene; 2016 Mar; 35(10):1328-33. PubMed ID: 26028035
[TBL] [Abstract][Full Text] [Related]
32. TGFβ induces epithelial-mesenchymal transition of thyroid cancer cells by both the BRAF/MEK/ERK and Src/FAK pathways.
Baquero P; Jiménez-Mora E; Santos A; Lasa M; Chiloeches A
Mol Carcinog; 2016 Nov; 55(11):1639-1654. PubMed ID: 26392228
[TBL] [Abstract][Full Text] [Related]
33. Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
Byeon HK; Na HJ; Yang YJ; Ko S; Yoon SO; Ku M; Yang J; Kim JW; Ban MJ; Kim JH; Kim DH; Kim JM; Choi EC; Kim CH; Yoon JH; Koh YW
Oncotarget; 2017 Jan; 8(1):596-609. PubMed ID: 27880942
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma.
Koperek O; Kornauth C; Capper D; Berghoff AS; Asari R; Niederle B; von Deimling A; Birner P; Preusser M
Am J Surg Pathol; 2012 Jun; 36(6):844-50. PubMed ID: 22592144
[TBL] [Abstract][Full Text] [Related]
35. Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAF(V600E) Mutation and BRAF Pseudogene.
Lin JD; Fu SS; Chen JY; Lee CH; Chau WK; Cheng CW; Wang YH; Lin YF; Fang WF; Tang KT
Thyroid; 2016 May; 26(5):691-704. PubMed ID: 26914762
[TBL] [Abstract][Full Text] [Related]
36. BRAF(V600E) mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas.
Durante C; Tallini G; Puxeddu E; Sponziello M; Moretti S; Ligorio C; Cavaliere A; Rhoden KJ; Verrienti A; Maranghi M; Giacomelli L; Russo D; Filetti S
Eur J Endocrinol; 2011 Sep; 165(3):455-63. PubMed ID: 21653734
[TBL] [Abstract][Full Text] [Related]
37. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
38.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
39. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
Friday BB; Yu C; Dy GK; Smith PD; Wang L; Thibodeau SN; Adjei AA
Cancer Res; 2008 Aug; 68(15):6145-53. PubMed ID: 18676837
[TBL] [Abstract][Full Text] [Related]
40. Suppression of B-Raf(V600E) cancers by MAPK hyper-activation.
Atiq R; Hertz R; Eldad S; Smeir E; Bar-Tana J
Oncotarget; 2016 Apr; 7(14):18694-704. PubMed ID: 26959890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]